# What the medical article titles are describing

> Growth Hormone Axis research peptides: the original papers — Growth Hormone Axis research peptides: original tesamorelin, sermorelin, and CJC-1295 papers on fat, growth, blood changes, and possible harm.

**16 sources about treatment, blood changes, and harm**

GH names growth hormone; GHRH prompts release. Growth hormone-releasing factor also names GHRH. Secretagogues are drugs prompting release. Insulin-like growth factor I means the liver's growth-supporting hormone.

## What unfamiliar words in these titles mean

Axis links hormones; analog or analogue means a drug copying a hormone. Hepatic means liver; visceral fat surrounds belly organs. Metabolic concerns food use. Endogenous means made by your body; serum means liquid in blood.

Randomized means chance chose treatments; a meta-analysis combines trials. Structured narrative reviews organize discussion of earlier studies; antidoping means bans on sports drugs. Subcutaneous means under skin; pulsatility or pulsatile secretion means release in bursts.

Cognitive impairment means trouble thinking; cognitive function means thinking ability. Lipodystrophy means unusual fat storage; a protein profile lists blood proteins. Pharmaceutical preparation means drug mixture.

## References

[1] Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity Research & Clinical Practice. 2026;20(1):2-12. https://pubmed.ncbi.nlm.nih.gov/41545261/
[2] National Institute of Diabetes and Digestive and Kidney Diseases (LiverTox). Tesamorelin - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf (NIH). 2018. https://www.ncbi.nlm.nih.gov/books/NBK548730/
[3] Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. https://pubmed.ncbi.nlm.nih.gov/25038357/
[4] Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. Journal of Clinical Endocrinology and Metabolism. 2011;96(1):150-158. https://pubmed.ncbi.nlm.nih.gov/20943777/
[5] Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. https://pubmed.ncbi.nlm.nih.gov/18690162/
[6] Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370. https://pubmed.ncbi.nlm.nih.gov/18057338/
[7] Villegas Meza AD, et al. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS reviews. 2026;14. https://pubmed.ncbi.nlm.nih.gov/42160466/
[8] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nature Reviews Endocrinology. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[9] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology. 2012;69(11):1420-1429. https://pubmed.ncbi.nlm.nih.gov/22869065/
[10] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Annals of Internal Medicine. 2008;149(9):677-9. https://pubmed.ncbi.nlm.nih.gov/18981489/
[11] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clinical Interventions in Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
[12] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Journal of Clinical Endocrinology and Metabolism. 1996;81(3):1189-96. https://pubmed.ncbi.nlm.nih.gov/8772599/
[13] Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. https://doi.org/10.1002/dta.233
[14] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[15] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[16] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/

---

Prestige Peptide is an independent GH-axis literature briefing that supplies assay and sampling context, never personal laboratory interpretation or medical advice.